SPRING PHARMACEUTICAL GROUP, INC. - FORM 10-K - EX-32 - CERTIFICATE PURSUANT TO 18 U.S.C. SS. 1350 - June 29, 2018

Attached files

file filename
EX-31.2 - RULE 13A-14(A) CERTIFICATE ? CFO - SPRING PHARMACEUTICAL GROUP, INC.exh31_2.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATE ? CEO - SPRING PHARMACEUTICAL GROUP, INC.exh31_1.htm
EX-10.8 - CHINA YCT INTERNATIONAL GROUP, INC. 2018 STOCK INCENTIVE PLAN DATED APRIL 21, 20 - SPRING PHARMACEUTICAL GROUP, INC.exh10_8.htm
EX-10.7 - ENGLISH TRANSLATION OF SUPPLEMENTARY AGREEMENT TO THE DIRECT SELLING AUTHORIZATI - SPRING PHARMACEUTICAL GROUP, INC.exh10_7.htm
EX-10.6 - ENGLISH TRANSLATION OF DIRECT SELLING AUTHORIZATION AGREEMENT BETWEEN SHANDONG S - SPRING PHARMACEUTICAL GROUP, INC.exh10_6.htm
EX-10.5 - ENGLISH TRANSLATION OF EMPLOYMENT AGREEMENT BETWEEN SHANDONG SPRING PHARMACEUTIC - SPRING PHARMACEUTICAL GROUP, INC.exh10_5.htm
EX-10.4 - AMENDED AND RESTATED ACER TRUNCATUM INDUSTRIAL PROJECT ACQUISITION AGREEMENT BET - SPRING PHARMACEUTICAL GROUP, INC.exh10_4.htm
EX-10 - ENGLISH TRANSLATION OF EMPLOYMENT AGREEMENT BETWEEN SHANDONG SPRING PHARMACEUTIC - SPRING PHARMACEUTICAL GROUP, INC.exh10_3.htm
EX-10.2 - ENGLISH TRANSLATION OF DISTRIBUTION AGREEMENT BETWEEN CHINA YCT INTERNATIONAL GR - SPRING PHARMACEUTICAL GROUP, INC.exh10_2.htm
10-K - 10K - SPRING PHARMACEUTICAL GROUP, INC.china.htm
Exhibits 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Annual Report of China YCT International Group, Inc. (the "Company") on Form 10K for the period ending March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: June 29, 2018 


                                                                                                                                           By:/s/ Tinghe Yan
                                                                                                                                               Tinghe Yan
              Principal Executive Officer

 Date: June 29, 2018 


                                                                                                                                           By:/s/ Chuanmin Li
                                                                                                                                                 Chuanmin Li
              Principal Financial Officer

 

SPRING PHARMACEUTICAL GROUP, INC. Reports